Polaris Group (TPEX:6550) - Share price, News & Analysis

6550 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

6550 Stock Overview

Polaris Group provides consulting services to post-acute health care providers in the United States.

Risk Analysis

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue (NT$15M)

Shareholders have been diluted in the past year

Polaris Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Polaris Group
Historical stock prices
Current Share Price	NT$109.00
52 Week High	NT$137.50
52 Week Low	NT$53.00
Beta	0.85
1 Month Change	-14.84%
3 Month Change	41.19%
1 Year Change	67.95%
3 Year Change	442.29%
5 Year Change	336.00%
Change since IPO	-1.21%

Shareholder Returns

	6550	TW Biotechs	TW Market
7D	-10.3%	-5.1%	-3.4%
1Y	68.0%	9.1%	0.7%

Return vs Industry: 6550 exceeded the TW Biotechs industry which returned 9.1% over the past year.

Return vs Market: 6550 exceeded the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6550's price volatile compared to industry and market?
6550 volatility
6550 Average Weekly Movement	10.7%
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6550 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 6550's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

Founded	Employees	CEO	Website
1988	n/a	n/a	https://www.polaris-group.com

Polaris Group provides consulting services to post-acute health care providers in the United States. The company offers medicare consulting services comprising of operations assessment and training and audits. It also offers mock surveys consisting of nursing facility, as well as clinical compliance consulting and infection control services.

Polaris Group Fundamentals Summary

How do Polaris Group's earnings and revenue compare to its market cap?
6550 fundamental statistics
Market Cap	NT$78.35b
Earnings (TTM)	-NT$740.49m
Revenue (TTM)	NT$15.04m

5,210x

P/S Ratio

-105.8x

P/E Ratio

Is 6550 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
6550 income statement (TTM)
Revenue	NT$15.04m
Cost of Revenue	NT$12.94m
Gross Profit	NT$2.10m
Other Expenses	NT$742.58m
Earnings	-NT$740.49m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.03
Gross Margin	13.94%
Net Profit Margin	-4,923.12%
Debt/Equity Ratio	5.5%

How did 6550 perform over the long term?

See historical performance and comparison

Valuation

Is Polaris Group undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

10.86x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6550's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6550's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6550 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6550 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6550's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6550 is overvalued based on its PB Ratio (10.9x) compared to the TW Biotechs industry average (3.8x).

Future Growth

How is Polaris Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

125.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Polaris Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Polaris Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

7.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6550 is currently unprofitable.

Growing Profit Margin: 6550 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6550 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare 6550's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 6550 has a negative Return on Equity (-10.26%), as it is currently unprofitable.

Financial Health

How is Polaris Group's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6550's short term assets (NT$6.3B) exceed its short term liabilities (NT$436.8M).

Long Term Liabilities: 6550's short term assets (NT$6.3B) exceed its long term liabilities (NT$171.5M).

Debt to Equity History and Analysis

Debt Level: 6550 has more cash than its total debt.

Reducing Debt: 6550's debt to equity ratio has reduced from 701.7% to 5.5% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6550 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6550 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 15.7% each year

Dividend

What is Polaris Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6550's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6550's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6550's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6550's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6550 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Polaris Group has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31